To study the potential correlation of MDGI expression with clinicopathological variables and patient survival, we performed immunohistochemistry for MDGI in human tumour microarrays (TMAs) consisting of lower WHO grade (grade II–III) gliomas and glioblastomas (grade IV; Fig 1A), and scored the staining intensity separately in tumour cells and tumour‐associated endothelial cells. This evidence concerns the gene FABP3 and central nervous system cancer.